Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL) over the age of 60 years or unable to receive standard ABVD chemotherapy: Results of a study of Academic and Community Cancer Research United (ACCRU) RU051505I. Cheson, B. D., Bartlett, N. L., LaPlant, B., Lee, H., Advani, R. H., Christian, B., Diefenbach, C., Feldman, T., Ansell, S. M. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000560368303235